Decoy Therapeutics Enhances Its IP Portfolio for Next-Gen Antivirals#USA#Cambridge#Decoy_Therapeutics#IMP3ACT_platform#Designable_Multi-Antivirals
Decoy Therapeutics Enhances Its IP Portfolio for Next-Gen Antivirals
Decoy Therapeutics has expanded its intellectual property portfolio, now encompassing seven patent families, enhancing its position in the antiviral space.
third-news.com
August 3, 2026 at 1:25 PM
Decoy Therapeutics Enhances Its IP Portfolio for Next-Gen Antivirals#USA#Cambridge#Decoy_Therapeutics#IMP3ACT_platform#Designable_Multi-Antivirals
Decoy Therapeutics Develops Scalable Peptide-Conjugate Manufacturing for Global Access#USA#Gates_Foundation#Cambridge#Decoy_Therapeutics#IMP3ACT_platform
Decoy Therapeutics Develops Scalable Peptide-Conjugate Manufacturing for Global Access
Decoy Therapeutics has announced a collaboration with the Gates Foundation to create a scalable manufacturing platform for peptide-conjugate antivirals aimed at improving global access, especially in low-income countries.
third-news.com
January 13, 2026 at 1:50 PM
Decoy Therapeutics Develops Scalable Peptide-Conjugate Manufacturing for Global Access#USA#Gates_Foundation#Cambridge#Decoy_Therapeutics#IMP3ACT_platform